Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serologic markers in inflammatory bowel disease.

Xavier Bossuyt1

  • 1Laboratory Medicine, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. Xavier.Bossuyt@uz.kuleuven.ac.be

Clinical Chemistry
|December 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methodology and quality assurance practices in performing anti-extractable nuclear antigen (ENA) analysis: an EFLM report on an international survey.

Clinical chemistry and laboratory medicine·2026
Same author

Autoantigen identification in antinuclear antibody-positive usual interstitial pneumonia without known autoantibody through immunoprecipitation-mass spectrometry.

ERJ open research·2026
Same author

Immunoprecipitation-mass spectrometry reveals known and novel (NatC, <i>BCS1L</i>) antinuclear antibodies in rheumatoid arthritis.

RMD open·2026
Same author

Interlaboratory variability in laboratory testing and reporting of myositis autoantibodies.

Journal of autoimmunity·2026
Same author

Prevalence of antisynthetase antibodies in a multicentre early rheumatoid arthritis cohort.

Acta clinica Belgica·2026
Same author

Development and validation of a flow cytometry-based ISG15 induction assay to monitor the type I interferon response.

Clinical immunology (Orlando, Fla.)·2025

This review examines key antibodies for diagnosing and managing inflammatory bowel disease (IBD). It highlights their role in differentiating Crohn disease and ulcerative colitis, and predicting treatment response.

Area of Science:

  • Gastroenterology
  • Immunology
  • Clinical Diagnostics

Background:

  • Inflammatory bowel disease (IBD) is a chronic condition primarily affecting young individuals, characterized by bloody diarrhea and abdominal pain.
  • Autoantibodies, including atypical perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA), are linked to IBD.
  • Understanding these antibody markers is crucial for effective IBD management.

Purpose of the Study:

  • To review the diagnostic and prognostic value of various antibodies in inflammatory bowel disease (IBD).
  • To assess the utility of p-ANCA and ASCA in differentiating IBD subtypes like Crohn disease and ulcerative colitis.
  • To explore the role of novel antimicrobial antibodies in IBD.

Main Methods:

Related Experiment Videos

  • Comprehensive literature review of studies investigating antibody markers in IBD.
  • Analysis of data concerning antibody associations with diagnosis, disease phenotype, and therapeutic response.
  • Inclusion of newly identified antimicrobial antibodies in the review.

    • Main Results:

    • p-ANCA and ASCA are valuable for diagnosing IBD and distinguishing between Crohn disease and ulcerative colitis.
    • Antibody profiles can help define clinical phenotypes, monitor disease activity, and predict treatment outcomes.
    • Emerging antimicrobial antibodies show potential as novel diagnostic and prognostic markers.

    Conclusions:

    • Antibodies play a significant role in the multifaceted management of inflammatory bowel disease.
    • Further research into novel antibody targets may enhance personalized IBD care.
    • Serological markers are essential tools for improving diagnostic accuracy and treatment strategies in IBD.